I remember when I started my investment journey (including the formal education process) many years ago, the 60/40 approach was deemed as the gold standard in terms of how to think about long-term investing.Roberts Berzins has over a decade of experience in the financial management helping top-tier corporates shape their financial strategies and execute large-scale financings. He has also made significant efforts to institutionalize REIT framework in Latvia to boost the liquidity of pan-Baltic capital marke ...

Vancouver, BC – TheNewswire - April 16, 2025 – GABO Mining Ltd. (TSXV: GAB | OTCQB: MLLOF | Frankfurt: MRDN) (the “Company” or “GABO”) is pleased to announce that a wholly owned subsidiary of the Company (Medallion Research USA, Inc.), has entered into a lease agreement dated April 14, 2025 with C Bar B Properties Corporation (the “Vendor”), pursuant to which the Company has been granted a four year lease, with exclusive option to purchase, two advanced-stage uranium exploration projects located in Utah an ...

Core Insights - The article discusses the investment landscape in the real estate sector, particularly focusing on the performance and potential of various real estate investment trusts (REITs) and housing-related companies [1][2]. Group 1: Company Insights - Hoya Capital Research & Index Innovations is affiliated with Hoya Capital Real Estate, which provides investment advisory services and focuses on publicly traded securities in the real estate industry [2]. - The commentary emphasizes that the information provided is for educational purposes and does not constitute investment advice [2][3]. Group 2: Industry Insights - The real estate industry is highlighted as having unique risks associated with investments in real estate companies and housing industry companies [2]. - The article notes that past performance of market data does not guarantee future results, indicating the volatile nature of the real estate market [3].

Core Insights - The article emphasizes the importance of dividend investing in quality blue-chip stocks, BDCs, and REITs for building a sustainable retirement income [1][2]. Group 1: Investment Strategy - The company adopts a buy-and-hold investment strategy, focusing on quality over quantity in its portfolio [1]. - The goal is to help lower and middle-class workers build investment portfolios that consist of high-quality, dividend-paying companies [1]. Group 2: Personal Investment Philosophy - The company aims to achieve financial independence through dividend income within the next 5-7 years [1]. - There is a strong emphasis on educating investors to conduct their own due diligence before making investment decisions [1].

LAUSANNE, Switzerland, April 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 8:00 a.m. ET. A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website, ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 da ...

However, several companies offer higher-yielding payouts for those seeking a bit more dividend income. Here are four top dividend stocks yielding around 4% these days that you can confidently buy for dividend income this April. Agree Realty Agree Realty (ADC 1.16%) has a 4% dividend yield. The real estate investment trust (REIT) focuses solely on owning single-tenant net lease and ground lease retail properties. Those lease structures provide very stable cash flow. Meanwhile, the REIT pays very close attent ...

Core Viewpoint - Agree Realty Corporation has launched its inaugural commercial paper program, allowing the issuance of up to $625 million in short-term, unsecured commercial paper notes to enhance its capital structure and provide liquidity for general corporate purposes [1][2]. Company Overview - Agree Realty Corporation is a publicly traded real estate investment trust (REIT) focused on acquiring and developing properties leased to leading omni-channel retail tenants. As of December 31, 2024, the company owned 2,370 properties across all 50 states, totaling approximately 48.8 million square feet of gross leasable area [4]. Financial Strategy - The commercial paper program is expected to diversify and strengthen the company's balance sheet by providing an additional source of short-term capital. The company anticipates cost benefits from the commercial paper market compared to its existing $1.25 billion revolving credit facility, which will serve as a liquidity backstop for the repayment of the notes issued [2].

Core Viewpoint - Agree Realty (NYSE: ADC) has experienced a nearly 9% increase year-to-date on a total return basis, contrasting with the broader downturn affecting REITs due to a significantly narrower outlook for Federal Reserve rate cuts in 2025 and rising long-term US yields [1] Group 1 - The equity market serves as a powerful mechanism where daily price fluctuations can lead to substantial wealth creation or destruction over the long term [1] - Pacifica Yield focuses on long-term wealth creation by targeting undervalued yet high-growth companies, high-dividend stocks, REITs, and green energy firms [1]

Core Insights - ADC Therapeutics reported significant progress in clinical trials for ZYNLONTA, with a 94% overall response rate (ORR) and a 72% complete response (CR) rate in the LOTIS-7 Phase 1b trial [1][5] - The company completed enrollment in the LOTIS-5 Phase 3 trial, with data updates expected in late 2025 [1][5] - Financial results for Q4 and full year 2024 showed a net product revenue of $16.4 million for Q4 and $69.3 million for the full year, indicating a slight increase compared to 2023 [8][22] Operational Updates - The LOTIS-7 trial demonstrated promising initial data, with 94% ORR and 72% CR in patients with relapsed or refractory non-Hodgkin lymphoma [5] - Enrollment for the LOTIS-5 trial was completed in December 2024, with data updates anticipated once progression-free survival (PFS) events are reached [5] - The company is also advancing its early research solid tumor program to the IND-enabling stage [2] Financial Performance - Q4 2024 net product revenues were $16.4 million, compared to $16.6 million in Q4 2023, while full-year revenues increased from $69.1 million in 2023 to $69.3 million in 2024 [8][22] - Research and development expenses decreased to $27.1 million for Q4 2024 from $30.3 million in Q4 2023, and full-year expenses dropped from $127.1 million to $109.6 million [8][22] - The net loss for Q4 2024 was $30.7 million, a significant reduction from $85.0 million in Q4 2023, and the full-year net loss decreased from $240.1 million to $157.8 million [8][22] Cash Position - As of December 31, 2024, the company had $250.9 million in cash and cash equivalents, down from $278.6 million in 2023, providing a runway expected to fund operations into the second half of 2026 [1][8]

Group 1 - ADC Therapeutics is positioned in the large B-cell lymphoma market with its antibody-drug conjugate [1] - The company has previously shown optimism in its market positioning, leading to a rally in stock price [1] - The author has a background in biochemistry and experience in analyzing clinical trials and biotech companies, emphasizing the importance of understanding the science behind investments [1]